Diabetes Care Veteran Named Biosensor Marketing Director at Trinity Biotech

David Ouston has joined Trinity Biotech plc as Biosensor Marketing Director. Ouston has a wealth of commercial experience driving the growth of glucose monitoring devices at large, established companies across global markets.
 
“We remain focused on our innovative, needle-free, reusable continuous glucose monitoring (CGM) technology as a key long-term growth driver for Trinity Biotech, and we are delighted to welcome David as a strategic appointment to our expanding team to help further this mission,” Trinity Biotech President/CEO John Gillard said. “His extensive global leadership experience in promotion and market access strategies for diabetes management devices and digital solutions will be a strong asset for Trinity Biotech as we prepare the roll out of our own CGM in rapidly growing diabetes and wellness markets.”
 
Ouston’s career spans 16 years in the glucose monitoring and diabetes health sectors, including global and EMEA regional marketing roles at Johnson & Johnson and LifeScan, where he led innovations in the OneTouch glucose monitoring portfolio. Previously, he worked in marketing positions at private healthcare provider Bupa, where he supported the promotion of their global healthcare brand.

Ouston earned a bachelor of arts degree in business administration from Brunel University in the United Kingdom.

“I am thrilled to join Trinity Biotech to help realize its vision for an accessible and innovative CGM in global markets,” Outson stated. “Trinity’s device offers a promising innovation in wearable biosensor technology and wellness analytics that can benefit more people globally to improve public health. I’m excited to work with this team in delivering a valuable solution to markets globally.”
 
Ireland-based Trinity Biotech is a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The company develops, acquires, manufactures, and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in more than 75 countries worldwide.